Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

36.22
+0.35771.00%
Post-market: 36.16-0.0550-0.15%19:30 EDT
Volume:3K
Turnover:90.56K
Market Cap:88.01M
PE:- -
High:36.23
Open:36.18
Low:35.96
Close:35.86
52wk High:39.48
52wk Low:33.59
Shares:2.43M
Float Shares:2.43M
Volume Ratio:0.36
T/O Rate:0.10%
Dividend:0.33
Dividend Rate:0.91%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

3 REIT Stocks Built To Handle Higher Rates

Simply Wall St.
·
7 hours ago

Chuxiong Prefecture Issues Implementation Plan for Establishing a Long-Term Care Insurance System

Deep News
·
9 hours ago

Healthpeak Properties Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
16 hours ago

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
17 hours ago

U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie

Reuters
·
20 hours ago

UBS Lifts AbbVie Target as Focus Expands Beyond Immunology Drugs

Reuters
·
Yesterday

TRex Bio indicated to open at $14.50, IPO priced at $14

TIPRANKS
·
Yesterday

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Yesterday

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Contec Medical Systems Secures Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System

Stock News
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Yesterday

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Yesterday

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Yesterday

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Yesterday

Island Pharmaceuticals Expands Unquoted Employee Options Pool

TIPRANKS
·
Yesterday